Testing spesolimab for pyoderma gangrenosum skin ulcers
Treatments studied
Part of Skin clinical trials.
This trial tests whether the drug spesolimab can help people with a skin condition called pyoderma gangrenosum, which causes painful ulcers. It's for adults who have at least one active ulcer that's at least 2 inches across and needs treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have a confirmed diagnosis of pyoderma gangrenosum with an active ulcer that's at least 2 inches across.
- Your ulcer must need treatment with strong medicine (not just creams or bandages).
- You cannot have other types of skin lesions or an ulcer that's bigger than about 4 inches across.
- You must be free of active infections (like tuberculosis, HIV, or hepatitis) or have completed treatment for them.
- Women who can get pregnant must use highly effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called bimekizumab to see if it helps people with pyoderma gangrenosum, a painful skin condition that causes deep ulcers. If you qualify, you'll receive the treatment and be monitored for about a year.
This study tests an experimental drug called SHR-1139 to see if it can help heal skin ulcers caused by pyoderma gangrenosum. If you qualify, you would receive the study drug and be monitored for safety and effectiveness.
This study tests an investigational drug called SHR-1139 for adult patients with ulcerative pyoderma gangrenosum (a type of painful skin ulcer). The goal is to see if the drug is safe and helps heal the ulcers.
This study tests a cream called ruxolitinib to treat pyoderma gangrenosum, a painful skin condition that causes deep ulcers. The cream is applied directly to the ulcer and may help it heal without the side effects of pills or injections.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This trial tests if guselkumab, a drug given as an injection under the skin, can help people with psoriatic arthritis (PsA) who haven't had enough relief from standard treatments. It aims to find a new option for managing joint pain and swelling.
Hear when a new Pyoderma Gangrenosum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.